← Back to Screener
Nkarta, Inc. Common Stock (NKTX)
Price$2.80
Favorite Metrics
Price vs S&P 500 (26W)11.80%
Price vs S&P 500 (4W)2.21%
Market Capitalization$172.52M
All Metrics
Book Value / Share (Quarterly)$4.39
P/TBV (Annual)0.35x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.26
Price vs S&P 500 (YTD)28.17%
EPS (TTM)$-1.41
10-Day Avg Trading Volume0.56M
EPS Excl Extra (TTM)$-1.41
EPS (Annual)$-1.60
ROI (Annual)-26.72%
Cash / Share (Quarterly)$3.89
ROA (Last FY)-21.75%
EBITD / Share (TTM)$-1.49
ROE (5Y Avg)-32.64%
Cash Flow / Share (Annual)$-1.26
P/B Ratio0.55x
P/B Ratio (Quarterly)0.42x
Net Income / Employee (Annual)$-1
ROA (TTM)-23.79%
EPS Incl Extra (Annual)$-1.60
Current Ratio (Annual)12.69x
Quick Ratio (Quarterly)12.41x
3-Month Avg Trading Volume0.71M
52-Week Price Return42.35%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$6.05
P/S Ratio (Annual)1437.69x
Asset Turnover (Annual)0.00x
52-Week High$2.81
EPS Excl Extra (Annual)$-1.60
CapEx CAGR (5Y)-30.61%
26-Week Price Return15.79%
Quick Ratio (Annual)12.52x
13-Week Price Return11.01%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)12.69x
Enterprise Value$132.889
Book Value / Share Growth (5Y)-14.92%
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-17566.67%
Cash / Share (Annual)$3.89
3-Month Return Std Dev71.10%
Net Income / Employee (TTM)$-1
ROE (Last FY)-26.72%
EPS Basic Excl Extra (Annual)$-1.60
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.41
ROI (TTM)-30.02%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$7.62
Price vs S&P 500 (52W)12.52%
Year-to-Date Return30.81%
5-Day Price Return3.42%
EPS Normalized (Annual)$-1.60
ROA (5Y Avg)-27.09%
Net Profit Margin (Annual)-17566.67%
Month-to-Date Return14.69%
Cash Flow / Share (TTM)$-2.41
EBITD / Share (Annual)$-1.47
Operating Margin (Annual)-19250.00%
ROI (5Y Avg)-32.64%
EPS Basic Excl Extra (TTM)$-1.41
P/TBV (Quarterly)0.43x
P/B Ratio (Annual)0.42x
Book Value / Share (Annual)$4.39
Price vs S&P 500 (13W)10.32%
Beta0.73x
Revenue / Share (TTM)$0.00
ROE (TTM)-30.02%
52-Week Low$1.60
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.15
4.15
4.15
4.25
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NKTXNkarta, Inc. Common Stock | — | — | — | — | $2.80 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Nkarta is a clinical-stage biopharmaceutical company developing off-the-shelf allogeneic natural killer (NK) cell therapies for cancer treatment. The company combines proprietary NK cell expansion technology with engineered cell recognition capabilities to enhance therapeutic targeting and persistence. This approach aims to generate an abundant supply of engineered NK cells that can identify and eliminate cancer cells while triggering durable immune responses.